EBITDA Margin ratio Analysis of MoonLake Immunotherapeutics - Deep Dive
WARN : Please note that some of the values may not be in base currency

Latest FY EBITDA Margin
Period Ending - Dec-23

0


Poor EBITDA Margin
Period Ending - Dec-22
0

Poor EBITDA Margin
Growth
0 %
Trailing Twelve Months EBITDA Margin
Period Ending - Dec-23

-222843352.10


Very Poor EBITDA Margin
Most recent Quarter EBITDA Margin
Period Ending - Mar-24

0


Poor EBITDA Margin
EBITDA Margin Analysis of MoonLake Immunotherapeutics
Ebitda Margin Ratio of MoonLake Immunotherapeutics with value of -222843352.10 means that its operating expenses are Higher in relation to total revenue in trailing twelve months.
Ebitda Margin Ratio of MoonLake Immunotherapeutics with value of 0 means that its operating expenses are Higher in relation to total revenue in latest Quarter ending on Mar-24.
EBITDA Margin Ratio of MLTX has fallen by 0 % Compared to previous Financial Year.
Ebitda Margin of MoonLake Immunotherapeutics is negative because of negative EBITDA in Trailing Twelve Months ended on Mar-24.
Other EBITDA Margin Related Info of MLTX that may interest you.
MoonLake Immunotherapeutics Overview
CodePricePrevious PricePrice ChangeSector
MLTX41.4142.71 3.04 % Biotechnology
Fundamental AnalysisTechnical Analysis
Defination of EBITDA Margin
EBITDA Margin is the profitability ratio that measures a company's earnings before interest, taxes, depreciation, and amortization as a percentage of revenue. EBITDA is the abbreviation for Earnings before Interest, Taxes, Depreciation, and Amortization.   more ..
EBITDA Margin Formula
EBITDA Margin Related Ratios
NetProfitMarginReturnOnEquity
Tsr Profitability Index
Poor Profitability Stock
FY - Historical EBITDA Margin of MoonLake Immunotherapeutics
PeriodDec-23Dec-22Dec-21Dec-20
EBITDA Margin0000
Change
FY Chart of EBITDA Margin of MoonLake Immunotherapeutics


Note : All Data Generated at the End of Trading Hours (EOD Data)